Insulin therapy in Europe

Area of Science:

• Endocrinology and Metabolic Diseases
• Public Health and Epidemiology

Background:

• Rising prevalence of type 1 diabetes (T1D) across European nations, with notable increases in Scandinavia and the UK.
• Established influence of landmark studies like DCCT and UKPDS on European insulin therapy, emphasizing tight metabolic control.
• The Saint Vincent Declaration's role in setting European goals for antidiabetic therapy, reinforcing glycemic control importance.

Purpose of the Study:

• To review advancements in insulin therapy for type 1 diabetes in Europe over the past decade.
• To identify persistent obstacles hindering optimal diabetes management and the reduction of long-term complications.

Main Methods:

• Review of clinical trial outcomes (DCCT, UKPDS) and policy declarations (Saint Vincent Declaration).
• Analysis of trends in insulin therapy adoption, including intensive regimens and novel insulin analogs.
• Identification of barriers to effective diabetes care based on professional guidelines and provider communication.

Main Results:

• Significant improvements in insulin therapy, marked by increased use of intensive insulin therapy and new insulin analogs (e.g., insulin glargine, short-acting agents for pumps).
• Development and implementation of standardized treatment goals and guidelines across Europe.
• Persistent challenges remain, including low public awareness of diabetes symptoms, inadequate physician and patient training, and fragmented inter-professional communication.

Conclusions:

• European insulin therapy for type 1 diabetes has advanced considerably due to research, new analogs, and standardized guidelines.
• Overcoming obstacles such as limited public awareness, insufficient training, and communication gaps is crucial for optimizing patient outcomes and minimizing diabetes complications.